Postmenopausal atrophic vaginitis

1. IL10RA lowers the risk of postmenopausal atrophic vaginitis in humans (OR: 0.906, 95% CI: 0.831-0.988).

   “IL10RA (OR: 0.906, 95% CI: 0.831-0.988), and TGFA (OR: 0.880, 95% CI: 0.790-0.981) were inversely associated with PAV risk.”

   Humans

   Causal Effects of Circulating Inflammatory Proteins on Postmenopausal Atrophic Vaginitis in European Populations: A Mendelian Randomization Study with Transcriptomic Validation

   International journal of women's health·29 Jul 2026

More on IL10RA

1. IL12B raises the risk of postmenopausal atrophic vaginitis in humans (OR: 1.050, 95% CI: 1.002-1.100).

   “IL12B (OR: 1.050, 95% CI: 1.002-1.100) were associated with increased PAV risk”

   Humans

   Causal Effects of Circulating Inflammatory Proteins on Postmenopausal Atrophic Vaginitis in European Populations: A Mendelian Randomization Study with Transcriptomic Validation

   International journal of women's health·29 Jul 2026

More on IL12B

1. CCL19 raises the risk of postmenopausal atrophic vaginitis in humans (OR: 1.063, 95% CI: 1.003-1.126).

   “CCL19 (OR: 1.063, 95% CI: 1.003-1.126) and IL12B (OR: 1.050, 95% CI: 1.002-1.100) were associated with increased PAV risk”

   Humans

   Causal Effects of Circulating Inflammatory Proteins on Postmenopausal Atrophic Vaginitis in European Populations: A Mendelian Randomization Study with Transcriptomic Validation

   International journal of women's health·29 Jul 2026

More on CCL19

1. TGFA lowers the risk of postmenopausal atrophic vaginitis in humans (OR: 0.880, 95% CI: 0.790-0.981).

   “TGFA (OR: 0.880, 95% CI: 0.790-0.981) were inversely associated with PAV risk.”

   Humans

   Causal Effects of Circulating Inflammatory Proteins on Postmenopausal Atrophic Vaginitis in European Populations: A Mendelian Randomization Study with Transcriptomic Validation

   International journal of women's health·29 Jul 2026

More on TGFA